Search research articles
Contact Us
Filters
Showing results (131-140 of 293) with videos related to
Page
of 30
Sort By:
Nature Communications
|
October 4, 2018
Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects
Allison A Regier, Yossi Farjoun, David E Larson, et al.
Nature Communications
|
February 16, 2021
Author Correction: Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder
Ditte Demontis, Raymond K Walters, Veera M Rajagopal, et al.
Nature Genetics
|
May 30, 2012
Exome sequencing and the genetic basis of complex traits
Adam Kiezun, Kiran Garimella, Ron Do, et al.
Nature
|
May 28, 2020
Mapping and characterization of structural variation in 17,795 human genomes
Haley J Abel, David E Larson, Allison A Regier, et al.
Science Translational Medicine
|
June 26, 2020
Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Jonas Bovijn, Kristi Krebs, Chia-Yen Chen, et al.
Nature Communications
|
January 26, 2021
Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder
Ditte Demontis, Raymond K Walters, Veera M Rajagopal, et al.
Cell Genomics
|
May 20, 2022
Genome-wide risk prediction of common diseases across ancestries in one million people
Nina Mars, Sini Kerminen, Yen-Chen A Feng, et al.
Nature Genetics
|
April 11, 2018
Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types
Hilary K Finucane, Yakir A Reshef, Verneri Anttila, et al.
Molecular Autism
|
May 27, 2014
Rare deleterious mutations of the gene EFR3A in autism spectrum disorders
Abha R Gupta, Michelle Pirruccello, Feng Cheng, et al.
Science Translational Medicine
|
December 1, 2021
Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics"
Jonas Bovijn, Kristi Krebs, Chia-Yen Chen, et al.
Page
of 30
Search research articles
Search
Showing results (131-140 of 293) with videos related to
Sort By:
Page
of 30
Nature Communications
|
October 4, 2018
Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects
Allison A Regier, Yossi Farjoun, David E Larson, et al.
Nature Communications
|
February 16, 2021
Author Correction: Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder
Ditte Demontis, Raymond K Walters, Veera M Rajagopal, et al.
Nature Genetics
|
May 30, 2012
Exome sequencing and the genetic basis of complex traits
Adam Kiezun, Kiran Garimella, Ron Do, et al.
Nature
|
May 28, 2020
Mapping and characterization of structural variation in 17,795 human genomes
Haley J Abel, David E Larson, Allison A Regier, et al.
Science Translational Medicine
|
June 26, 2020
Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Jonas Bovijn, Kristi Krebs, Chia-Yen Chen, et al.
Nature Communications
|
January 26, 2021
Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder
Ditte Demontis, Raymond K Walters, Veera M Rajagopal, et al.
Cell Genomics
|
May 20, 2022
Genome-wide risk prediction of common diseases across ancestries in one million people
Nina Mars, Sini Kerminen, Yen-Chen A Feng, et al.
Nature Genetics
|
April 11, 2018
Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types
Hilary K Finucane, Yakir A Reshef, Verneri Anttila, et al.
Molecular Autism
|
May 27, 2014
Rare deleterious mutations of the gene EFR3A in autism spectrum disorders
Abha R Gupta, Michelle Pirruccello, Feng Cheng, et al.
Science Translational Medicine
|
December 1, 2021
Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics"
Jonas Bovijn, Kristi Krebs, Chia-Yen Chen, et al.
Page
of 30